跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
prodrug 1
首页
药物
prodrug 1
prodrug 1
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Prodrugs of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone
US 12649754 B2
申请人: UCB BIOPHARMA SRL
优先权: 2020
CN
EP
US
WO
6 件公开
SUSTAINED RELEASE DRUG DELIVERY SYSTEM CONTAINING CODRUGS
EP 1383504 A1
申请人: CONTROL DELIVERY SYS INC
优先权: 2001
CN
EP
US
6 件公开
Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
US 7435833 B2
申请人: ABBOTT LAB
优先权: 2006
CN
EP
US
6 件公开
CN 101415675 A
申请人: ABBOTT LAB
优先权: 2006
CN
FORMULATED AND/OR CO-FORMULATED LIPOSOME COMPOSITIONS CONTAINING PD-1 ANTAGONIST PRODRUGS USEFUL IN THE TREATMENT OF CANCER AND METHODS THEREOF
EP 4211144 A1
申请人: NAMMI THERAPEUTICS INC
优先权: 2020
CN
EP
US
6 件公开
Enhanced drug delivery in transdermal systems
US 7456159 B2
申请人: NOVEN PHARMA
优先权: 2002
US
6 件公开
Compositions comprising enzyme-cleavable oxycodone prodrug
US 8569228 B2
申请人: JENKINS THOMAS E
优先权: 2012
US
6 件公开
US 8497237 B2
申请人: JENKINS THOMAS E
优先权: 2012
US
2 件公开
TARGETED PROTEIN DEGRADATION USING PRODRUGS OF BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN
EP 4630415 A1
申请人: CAPTOR THERAPEUTICS S A
优先权: 2022
CN
EP
US
WO
5 件公开
IBUPROFEN ESTER PRODRUG, PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD AND USE
EP 3984989 A4
申请人: NANJING HERON PHARMACEUTICAL SCIENCE AND TECH CO LTD
优先权: 2020
CN
EP
US
WO
4 件公开
PHARMACEUTICAL COMPOSITION COMPRISING NEUROKININ-1 ANTAGONIST PRODRUG COMPOUND
EP 4464320 C0
申请人: JIANGSU HENGRUI PHARMACEUTICALS CO LTD
优先权: 2022
CN
EP
US
WO
4 件公开
CRYSTAL FORM OF NEUROKININ-1 ANTAGONIST PRODRUG COMPOUND
EP 4464712 A4
申请人: JIANGSU HENGRUI PHARMACEUTICALS CO LTD
优先权: 2022
CN
EP
US
WO
4 件公开
第 1 / 10 页
上一页
下一页
药物
反馈